Cellular Therapy
News
FDA addresses cell-based regenerative medicine in comprehensive new policy
Clarifying the existing regulations will “promote responsible and flexible regulation that leverages science to advance public health,” according...
News
FDA approves letermovir for CMV prophylaxis
The FDA approved the use of letermovir tablets and injections to prevent CMV infection and disease in adults exposed to the virus who have had an...
Conference Coverage
Anidulafungin effectively treated invasive pediatric candidiasis in open-label trial
SAN DIEGO – The intravenous echinocandin anidulafungin effectively treated invasive candidiasis in children, with a safety profile resembling that...
Conference Coverage
Tocilizumab looks promising for corticosteroid refractory anti-PD-1-related adverse events
CHICAGO – In a review of patients treated with nivolumab, 27 of 34 who were refractory to corticosteroids and treated with tocilizumab for high-...
From the Journals
Off-the-shelf T cells used to treat viral infections after HSCT
Study suggests an effective way to get around the limitations of adoptive VST transfer.
From the Journals
ALLOZITHRO trial: HSCT patients fared worse with azithromycin
Early azithromycin in patients undergoing allogeneic hematopoietic stem cell transplant resulted in worse airflow decline–free survival than did...
Conference Coverage
Alopecia may be permanent in one in four pediatric HSCT patients
Diffuse hair thinning and psoriasis were among the late dermatologic effects in children who had received a hematopoietic stem cell transplant in...
News
Ibrutinib becomes first FDA-approved treatment for chronic GVHD
Ibrutinib (Imbruvica) added another notch on its indications belt with its August 2 approval by the U.S. Food and Drug Administration for the...
Conference Coverage
Bone marrow transplantation for epidermolysis bullosa continues to evolve
Today, bone marrow transplantation is the most widely used stem cell therapy for patients with severe EB.
Conference Coverage
Four drugs better than three for myeloma induction
MADRID – Adding the proteasome inhibitor carfilzomib to induction regimens delivered quicker and deeper remissions.
From the Journals
Allele-matching in cord blood transplant yields better survival
Matching down to the allele level in umbilical cord blood transplantation between unrelated donors results in greater overall survival for those...